PRESS RELEASES

JJP Biologics announces positive recommendation of Dose Escalation Committee to next dose level of its ongoing Phase I Clinical Trial of JJP-1212

JJP Biologics announces a positive recommendation from the Phase I Dose Escalation Committee to move to second cohort in the ongoing single ascending dose (SAD)…

JJP Biologics announces positive decision to execute a First-in-Human clinical trial of anti-inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212…

JJP Biologics opens its own research laboratory in Poland

JJP Biologics acquires Recepton’s R&D facilities and antibody-engineering/ production expertise, strengthening discovery and R&D capabilities to support the growing innovative pipeline. March 27, 2024 Warsaw,…

JJP Biologics announces successful manufacturing of first clinical GMP drug substance and drug product batch for intravenous administration of JJP-1212 (a potential…

The successful manufacturing of intravenous JJP-1212 drug product ensures sufficient supply for initiation of JJP Biologics’s first-ever Phase I clinical trial in healthy subjects June…

JJP Biologics announces that the European Commission Has Designated JJP-1212 as an Orphan Medicinal Product

JJP-1212, a first-in-class CD89 antagonist is being developed for the treatment of the rare autoimmune skin blistering disease linear IgA bullous dermatosis in addition to…